A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder.

A pilot comparison of the safety and efficacy of methylphenidate (MPH) combined with clonidine, clonidine monotherapy, or MPH monotherapy in 6- to 16-year-old children diagnosed with attention deficit hyperactivity disorder (ADHD) and comorbid aggressive oppositional defiant disorder or conduct disorder was completed. Study design was a 3-month, randomized, blinded, group comparison with eight subjects per group. No placebo comparison was used. All three treatment groups showed significant improvements in attention deficits, impulsivity, oppositional, and conduct disordered symptoms as assessed by parent and teacher rating scales and laboratory measures. Significant differences among treatment groups were found only on a few measures. Only the clonidine monotherapy group showed significantly decreased fine motor speed. These results suggest the safety and efficacy of clonidine alone or in combination with MPH for the treatment of ADHD and aggressive oppositional and conduct disorders.
AuthorsD F Connor, R A Barkley, H T Davis
JournalClinical pediatrics (Clin Pediatr (Phila)) Vol. 39 Issue 1 Pg. 15-25 (Jan 2000) ISSN: 0009-9228 [Print] UNITED STATES
PMID10660814 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic alpha-Agonists
  • Central Nervous System Stimulants
  • Methylphenidate
  • Clonidine
  • Adolescent
  • Adrenergic alpha-Agonists (therapeutic use)
  • Aggression (drug effects)
  • Attention Deficit Disorder with Hyperactivity (complications, drug therapy)
  • Central Nervous System Stimulants (therapeutic use)
  • Child
  • Clonidine (administration & dosage, adverse effects, therapeutic use)
  • Conduct Disorder (drug therapy, etiology)
  • Confounding Factors (Epidemiology)
  • Double-Blind Method
  • Drug Therapy, Combination
  • Humans
  • Male
  • Methylphenidate (administration & dosage, therapeutic use)
  • Pilot Projects
  • Psychiatric Status Rating Scales
  • Psychomotor Performance (drug effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: